ライフサイエンスコーパス: cachectic

1 Twelve patients were cachectic.

2 population, 16% of patients were found to be cachectic.

3 within 2 weeks) developed ascites and became cachectic.

4 1) less comorbidity, (2) cardiovascular, (3) cachectic, (4) metabolic, and (5) psychological.

5 eart failure (CHF), classified clinically as cachectic (8% to 35% weight loss over > or = 6 months be

6 th untreated iMSUD mice, which were severely cachectic and died </=28 days after birth.

7 (>500 mg/dL), hyperketonemic, polyuric, and cachectic and had to be killed after 6 weeks.

8 Most cachectic and some noncachectic patients with CHF show f

9 s (mean age, 61.9+/-10.9 years; 95% male; 25 cachectics) and 24 age-matched normal subjects (mean age

10 Weight loss in cachectic animals was also associated with a depletion o

11 Of these, 68 cachectic (body mass index [BMI]<20 kg/m2), 113 overweig

12 Surprisingly, the Cre(+) mice became cachectic by postnatal day 80 due to bilateral GCT.

13 l compared EPA diethyl ester with placebo in cachectic cancer patients for effects on weight and lean

14 he 24K material was also present in urine of cachectic cancer patients, but was absent from normal su

15 2 on the alpha-subunit in skeletal muscle of cachectic cancer patients, which would lead to muscle at

16 Cachectic CHF patients are weaker and fatigue earlier.

17 Cachectic CHF patients show increased plasma levels of c

18 Plasma leptin levels are elevated in non-cachectic CHF, suggesting the possibility that leptin mi

19 one in impeding muscle protein catabolism in cachectic, critically injured children.

20 acts very differently than the prototypical cachectic cytokine, IL-1.

21 perhaps more analogous to those activated by cachectic cytokines.

22 rogeroid features, including short lifespan, cachectic dwarfism, lordokyphosis, cataracts, loss of su

23 bnormalities, sensorineural hearing loss and cachectic dwarfism.

24 system with the purpose of identifying early cachectic events.

25 in urine of most patients, and to which the cachectic factor is noncovalently bound.

26 ate the expression of muscle proteins may be cachectic factor specific.

27 The 24-kDa peak may be identified as the cachectic factor, a glycoprotein, whereas the peak at 67

28 o and in vivo models of muscle wasting, that cachectic factors are remarkably selective in targeting

29 exactly which products are targeted by these cachectic factors is not well understood.

30 ble to counteract the detrimental effects of cachectic factors on myogenic differentiation.

31 Similar changes were found when the cachectic group was compared with the control group.

32 is an anabolic steroid that has been used in cachectic hepatitis and AIDS patients.

33 loss, raising concerns that it might produce cachectic-like effects.

34 more, Pax7 was induced by serum factors from cachectic mice and patients, in an NF-kappaB-dependent m

35 so declined in Tibialis Anterior muscle from cachectic mice bearing murine colon adenocarcinoma or hu

36 ock myostatin pathway signaling in normal or cachectic mice leads to hypertrophy or prevention of mus

37 These changes persisted when cachectic mice were acclimatized to 28 degrees C confirm

38 e results suggest that UBR2 up-regulation in cachectic muscle is mediated by the p38beta-C/EBPbeta si

39 Cachectic muscle wasting is a frequent complication of m

40 of this pathway (that is, SDF1 or CXCR4) in cachectic muscles increased the fiber area by 20%, prote

41 whose expression is specifically altered in cachectic muscles of Yoshida hepatoma-bearing rodents bu

42 were significantly changed in the irradiated cachectic NHP compared to the non-irradiated NHP.

43 Radiographic imaging indicated that cachectic NHP lost as much as 50% of skeletal muscle.

44 he ergoreflex was particularly overactive in cachectics (P<0.05), accompanied by marked muscle mass d

45 Mortality in the cachectic patients (n = 28) was 18% at 3 months, 29% at

46 Dehydroepiandrosterone was reduced in the cachectic patients (P<.02 versus control subjects).

47 ion are increased in both morbidly obese and cachectic patients compared with normal-weight recipient

48 not increased in morbidly obese patients but cachectic patients had a significantly lower incidence o

49 Compared with healthy control subjects, cachectic patients had reduced (appendicular) muscle mas

50 control subjects and noncachectic patients, cachectic patients had reduced plasma sodium and increas

51 Cachectic patients had the lowest blood flow (p < 0.002)

52 Cachectic patients receiving oversized donor hearts had

53 Cachectic patients showed an increase of total GH and im

54 In cachectic patients with advanced cancer, oral melatonin

55 th factor-I (IGF-I) axis were compared in 21 cachectic patients with CHF, 51 noncachectic patients an

56 Shortened survival applies particularly to cachectic patients with localized disease, thereby reinf

57 3B gradually increased from precachectic to cachectic patients, without differences in E3 ubiquitin

58 exercise limitation in CHF, particularly in cachectic patients.

59 ed weight loss in Alzheimer disease, even in cachectic patients.

60 In the cachectic population, the ventilatory response from ergo

61 crease muscle mass in athletes and also aged/cachectic populations.

62 istal loss of muscle and fat mass during the cachectic process is still not deeply investigated.

63 y was seen at 30 days for morbidly obese and cachectic recipients (12.7% and 17.7%, respectively) ver

64 Morbidly obese as well as cachectic recipients demonstrated nearly twice the 5-yea

65 patients and the use of oversized donors in cachectic recipients should be avoided.

66 We sought to find out whether the cachectic state in CHF provides additional prognostic in

67 The cachectic state is a strong independent risk factor for

68 The cachectic state is predictive of poor survival independe

69 The cachectic state was predictive of 18-month mortality ind

70 ss of estrogen treatment alone on BMD in the cachectic state.

71 L-1alpha, IL-1beta, and TNFalpha can mediate cachectic states, how these molecules affect energy expe

72 The cachectic status was defined prospectively as a non-inte

73 e N-end rule pathway that is up-regulated by cachectic stimuli including proinflammatory cytokines an

74 The patients with RA were cachectic (their body cell mass was 14% lower than that

75 aller and exhibited profound delipidation in cachectic tumor-bearing mice.

76 S) confirmed the high tCho level observed in cachectic tumors that occurred because of an increase of

77 to identify metabolic signatures typical of cachectic tumors, using this information to analyze the

78 lower creatine levels were also detected in cachectic tumors.